Concepedia

Linjie Ma

LM

Statistics

Publications

4

Citations

131

H-Index

4

Active since

2023

Affiliations

Regend Therapeutics (China)(Current)

Sun Yat-sen University

Forma Therapeutics (United States)

Guangdong Pharmaceutical University

Northwest University

Linjie Ma is an author at Regend Therapeutics (China) specializing in oncology, molecular oncology, and antibody-drug conjugates.

ORCID

Publications per year

2023–2023

4

Publications

4

Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer

Weining Weng, Tao Meng, Qianqian Zhao et al. · Cancer Discovery · 2023 · 76 citations

, , +17

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weining Weng, Tao Meng, Junyi Pu et al. · Molecular Cancer Therapeutics · 2023 · 26 citations · Full text

, , +17

A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma

Jing Shi, Tao Jiao, Qian Guo et al. · Cancer Research · 2023 · 15 citations · Full text

, , +16

MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors

Chao Kong, Junyi Pu, Qianqian Zhao et al. · Molecular Cancer Therapeutics · 2023 · 14 citations · Full text

, , +17

1–4 of 4